BNP Paribas Arbitrage SA lessened its stake in shares of bluebird bio Inc (NASDAQ:BLUE) by 30.9% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 12,765 shares of the biotechnology company’s stock after selling 5,718 shares during the period. BNP Paribas Arbitrage SA’s holdings in bluebird bio were worth $2,008,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in BLUE. Dimensional Fund Advisors LP grew its holdings in bluebird bio by 1.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 133,711 shares of the biotechnology company’s stock worth $19,521,000 after acquiring an additional 2,191 shares during the last quarter. Man Group plc grew its holdings in bluebird bio by 95.8% during the 3rd quarter. Man Group plc now owns 6,109 shares of the biotechnology company’s stock worth $891,000 after acquiring an additional 2,989 shares during the last quarter. Neuberger Berman Group LLC grew its holdings in bluebird bio by 16.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 7,199 shares of the biotechnology company’s stock worth $1,051,000 after acquiring an additional 991 shares during the last quarter. Legal & General Group Plc grew its holdings in bluebird bio by 5.3% during the 3rd quarter. Legal & General Group Plc now owns 23,983 shares of the biotechnology company’s stock worth $3,501,000 after acquiring an additional 1,201 shares during the last quarter. Finally, Belpointe Asset Management LLC bought a new stake in bluebird bio during the 3rd quarter worth about $110,000.
Shares of NASDAQ:BLUE opened at $147.31 on Tuesday. The company has a market capitalization of $7.90 billion, a P/E ratio of -13.79 and a beta of 2.50. bluebird bio Inc has a fifty-two week low of $87.49 and a fifty-two week high of $199.70.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($2.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.79) by ($0.20). The firm had revenue of $12.47 million during the quarter, compared to analyst estimates of $15.49 million. bluebird bio had a negative net margin of 1,184.01% and a negative return on equity of 33.96%. The business’s revenue was down 21.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.31) earnings per share. Research analysts predict that bluebird bio Inc will post -11.62 earnings per share for the current fiscal year.
BLUE has been the topic of a number of research reports. JPMorgan Chase & Co. restated a “buy” rating on shares of bluebird bio in a research report on Thursday, January 10th. BMO Capital Markets upped their target price on shares of bluebird bio to $194.00 and gave the company an “outperform” rating in a research report on Friday, February 22nd. Cowen initiated coverage on shares of bluebird bio in a research report on Tuesday, February 26th. They set an “outperform” rating and a $149.91 target price on the stock. Zacks Investment Research downgraded shares of bluebird bio from a “hold” rating to a “sell” rating in a research report on Monday, February 11th. Finally, Oppenheimer restated a “hold” rating on shares of bluebird bio in a research report on Friday, January 11th. Nine research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. bluebird bio currently has a consensus rating of “Buy” and an average price target of $169.43.
In other bluebird bio news, insider David Davidson sold 4,910 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $155.77, for a total transaction of $764,830.70. Following the sale, the insider now directly owns 36,526 shares in the company, valued at approximately $5,689,655.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jason Cole sold 6,248 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $150.24, for a total transaction of $938,699.52. Following the sale, the insider now owns 28,692 shares in the company, valued at $4,310,686.08. The disclosure for this sale can be found here. Insiders sold a total of 25,170 shares of company stock worth $3,824,876 over the last quarter. 3.00% of the stock is currently owned by corporate insiders.
WARNING: This article was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.thelincolnianonline.com/2019/05/07/bnp-paribas-arbitrage-sa-sells-5718-shares-of-bluebird-bio-inc-blue.html.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
See Also: Stop Order Uses For Individual Investors
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.